Health sciences

AHF Salutes President Biden for Supporting Vaccine Patents Waiver

Retrieved on: 
Thursday, May 6, 2021
White House, Federal Government, AIDS, Public policy, Government, Health, Infectious diseases, Other Policy Issues, Pharmaceutical, Medical research, Vaccination, Vaccine, Virology, COVID-19 vaccine, Medical specialties, Medicine, Health sciences

We salute President Biden for taking a resolutely principled position in favor of waiving COVID-19 vaccine patents,\xe2\x80\x9d said AHF President Michael Weinstein.

Key Points: 
  • We salute President Biden for taking a resolutely principled position in favor of waiving COVID-19 vaccine patents,\xe2\x80\x9d said AHF President Michael Weinstein.
  • Once we clear the patents hurdle, countries need to quickly get on with the job of ramping up vaccine production.
  • If the WTO is successful in adopting a resolution on an IP waiver, this should pave the way for generic pharmaceutical companies to enter the market.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505006205/en/\n'

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 5, 2021
Health sciences, Health, Food and Drug Administration, Clinical research, Clinical trial, Design of experiments, Drug discovery

The FDA\xe2\x80\x99s grant of Breakthrough is an acknowledgment of the significant unmet need for patients with type 1 diabetes, and the encouraging clinical results we have generated to date,\xe2\x80\x9d said Steve Holcombe, president and CEO, vTv Therapeutics.

Key Points: 
  • The FDA\xe2\x80\x99s grant of Breakthrough is an acknowledgment of the significant unmet need for patients with type 1 diabetes, and the encouraging clinical results we have generated to date,\xe2\x80\x9d said Steve Holcombe, president and CEO, vTv Therapeutics.
  • vTv expects to report topline results from the mechanistic study in the third quarter of 2021.\nPivotal Study Planning.
  • The Company is planning to initiate the first of two pivotal, placebo-controlled, six-month clinical trials of TTP399 in subjects with type 1 diabetes in the fourth quarter of 2021.
  • The revenue for the first quarter was non-cash and related to the recognition of revenue pertaining to the Huadong license agreement.

MeiraGTx Announces Participation at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021
Branches of biology, Health sciences, Organ systems, Saliva, XC2, Xerostomia, Salivary gland, Sjögren syndrome, Therapy, Neurodegeneration, Retina

b'LONDON\xc2\xa0and\xc2\xa0NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings\xc2\xa0plc\xc2\xa0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\xc2\xa0Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May.\nLive webcasts of the presentations (where applicable) will be on the Investors page of the Company\xe2\x80\x99s website at www.investors.meiragtx.com .

Key Points: 
  • b'LONDON\xc2\xa0and\xc2\xa0NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings\xc2\xa0plc\xc2\xa0(Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that\xc2\xa0Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May.\nLive webcasts of the presentations (where applicable) will be on the Investors page of the Company\xe2\x80\x99s website at www.investors.meiragtx.com .
  • Led by an experienced management team,\xc2\xa0MeiraGTx\xc2\xa0has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications.
  • MeiraGTx\xe2\x80\x99s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia.
  • Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.\n'

Verana Health Leads First-of-its-Kind Study Demonstrating Promise of Real-World Data in Ophthalmic Clinical Development

Retrieved on: 
Wednesday, May 5, 2021
Data management, Health, Technology, Software, Clinical trials, General Health, Clinical research, Health sciences, Health, Medical research, Design of experiments, Evidence, Health informatics, Real world data, Clinical trial, Randomized controlled trial, Ophthalmology, Verana Health, the American Academy of Ophthalmology, VERANA HEALTH, THE AMERICAN ACADEMY OF OPHTHALMOLOGY

In a first-of-its kind study , Verana Health demonstrated that it was able to successfully use real world data (RWD) to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology\xe2\x80\x94the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials.

Key Points: 
  • In a first-of-its kind study , Verana Health demonstrated that it was able to successfully use real world data (RWD) to replicate primary outcome measures of two large-scale randomized controlled trials (RCTs) in ophthalmology\xe2\x80\x94the VIEW 1 and VIEW 2 (VIEW 1/2) pivotal trials.
  • The groundbreaking replication of the VIEW 1/2 clinical trials outcomes data shows the potential value real-world data can bring in helping to accelerate clinical trials," said David W. Parke II, MD, CEO of the American Academy of Ophthalmology.
  • "The research demonstrating the viability of linking imaging metadata to IRIS Registry encounters is also encouraging.
  • Currently, the IRIS Registry does not contain images, yet they are a critical component of the daily practice of ophthalmology.

Houston Moving Company Provides On-Site COVID-19 Vaccination Clinic

Retrieved on: 
Wednesday, May 5, 2021
BioNTech, Health sciences, COVID-19, Medical research, Companies, Pfizer, Pfizer–BioNTech COVID-19 vaccine, BioNTech, COVID-19 vaccination in Italy, COVID-19 vaccination in Canada

Most importantly, this on-site vaccination clinic was not just available to employees and contractors.

Key Points: 
  • Most importantly, this on-site vaccination clinic was not just available to employees and contractors.
  • It was opened up to friends, neighbors, or anyone that the employees knew of that still needed to be vaccinated.
  • It is in the spirit of these values that the local moving company chose to delay jobs the morning of Friday, April 30 to allow Houston moving and packing crews to attend the on-site clinic and receive the first dose of the Pfizer-BioNTech vaccine.
  • With offices in Houston , San Antonio , Austin , and Dallas , our local moving company has become recognized as the mover of choice for over 30,000 Texans each year.\n'

7 Million COVID Vaccines Administered With CureMD Vaccine Management System

Retrieved on: 
Wednesday, May 5, 2021
Medical research, Vaccination, Vaccine, Virology, COVID-19 vaccine, Medical specialties, Medicine, Health sciences

b'NEW YORK, May 5, 2021 /PRNewswire-PRWeb/ --CureMD Healthcare, the leader in SMART Cloud Health IT solutions, announced today that over 7 million patients have been administered COVID vaccines using its vaccine management system.

Key Points: 
  • b'NEW YORK, May 5, 2021 /PRNewswire-PRWeb/ --CureMD Healthcare, the leader in SMART Cloud Health IT solutions, announced today that over 7 million patients have been administered COVID vaccines using its vaccine management system.
  • Within a few months, several state and local government agencies, hospitals and healthcare facilities have partnered with CureMD to streamline patient outreach and scheduling; personalized reminders, contactless check-in with integrated inventory management.
  • said Bilal Hashmat, CEO at CureMD Healthcare.\nCureMD assist governments, public and private healthcare facilities, businesses, educational institutions and nonprofit organizations customize, and deploy vaccine programs at unprecedented scale.
  • The ability to create personalized communications campaigns, self-service scheduling, automated notifications, inventory management and administration, to help ensure quick and equitable distribution of life saving vaccines for people in need.\n'

CBD Healthcare company Opticann launches ArthroCBD, a line of scientifically proven softgel capsules

Retrieved on: 
Wednesday, May 5, 2021
Herbalism, Medicinal plants, Cannabis smoking, Health sciences, Psychoactive drugs, Life sciences, Medicinal chemistry, Antiemetics, Medical cannabis, Bioavailability, OTC Markets Group, Drug

Much of the problem with other CBD products is the lack of effect due to poor absorption as only 8-10% of product is absorbed.

Key Points: 
  • Much of the problem with other CBD products is the lack of effect due to poor absorption as only 8-10% of product is absorbed.
  • Opticann\'s US products use VESIsorb, a proven technology that helps boost the performance of pharmaceutical and wellness products.
  • Opticann sells science-backed products made with the patented VESIsorb drug delivery system for optimized absorption and stability (bioavailability).
  • Opticann is owned by Heritage Cannabis Holdings Corp., a Toronto-based publicly traded corporation (CSE: CANN) (OTCQX: HERTF).

Global Fatty Liver Disease Clinical Trials Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021
Health, Clinical trials, Other Health, Health sciences, Clinical research, Pharmaceutical industry, Health, Medical research, Clinical trials, Drug discovery, Design of experiments

b'The "Fatty Liver Disease - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com\'s offering.\nThis report provides top line data relating to the clinical trials on Fatty Liver Disease.

Key Points: 
  • b'The "Fatty Liver Disease - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com\'s offering.\nThis report provides top line data relating to the clinical trials on Fatty Liver Disease.
  • Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.\nThe report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nThe report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'

CME Outfitters Launches Pharmacist Central for Continuing Education

Retrieved on: 
Wednesday, May 5, 2021
Health sciences, Health, Pharmacy, Pharmacist

As pharmacy practice scope continues to broaden, so do pharmacists\' education needs.

Key Points: 
  • As pharmacy practice scope continues to broaden, so do pharmacists\' education needs.
  • CMEO Pharmacist Central is committed to providing these valuable care-team members with the latest data, best practices, and innovations to improve patient outcomes.
  • CME Outfitters also offers expert accreditation, outcome and logistics services for non-accredited organizations.
  • In July of 2020, CME Outfitters became part of KnowFully Learning Group, a leading provider of continuing professional education and exam preparation courses to the healthcare and financial services sectors.

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

Retrieved on: 
Wednesday, May 5, 2021
Medicinal plants, Psychoactive drugs, Euphoriants, Entheogens, Health sciences, Herbalism, Cannabis smoking, Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Cannabis, Chronic obstructive pulmonary disease, Medical cannabis

b'Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • b'Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.\nLast year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.\n'